BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bristol-Myers Squibb Company (BMY) And Pierre Fabre Medicament Enter Into Agreement To Develop And Commercialize Oncology Treatment Javlor(R) (vinflunine)


10/19/2005 5:10:57 PM

PRINCETON, N.J., and PARIS, April 20 /PRNewswire-FirstCall/ -- Bristol- Myers Squibb Company and Pierre Fabre Medicament S.A., a privately held pharmaceutical company headquartered in France, today announced that they have entered into an agreement to develop and commercialize Javlor(R) (vinflunine), a novel investigational anti-cancer agent. Javlor is currently in Phase III clinical trials in Europe for the treatment of bladder and non- small cell lung cancer, and Phase II clinical trials in breast and ovarian cancer. The agreement is subject to clearance under the Hart Scott Rodino Antitrust Improvements Act of 1976.

"We are particularly satisfied to be partnering Javlor with a premier oncology company like Bristol-Myers Squibb. The collaboration underlines the expertise of our group's research department in the area of oncology, our main research area," said Dr. Jean-Pierre Couzinier, Pierre Fabre Medicament Chief Operating Officer. "This agreement is a perfect illustration of our partnership oriented strategy, both in terms of product development and commercialization, in the large territories of North America and Japan," he added.

"Javlor is an important addition to our oncology portfolio that already includes multiple treatments to combat cancer, as well as a promising pipeline," said Peter R. Dolan, chairman and chief executive officer, Bristol- Myers Squibb. "In line with our new corporate strategy to focus on ten specific disease areas, including oncology, we are committed to both the discovery of new cancer therapies and working with innovative partners to bring new medicines to patients. We look forward to teaming up with a pioneering company such as the Pierre Fabre Group to further the clinical development of this important anti-cancer agent."

Under the terms of the agreement, Bristol-Myers Squibb will receive an exclusive license to Javlor in the United States, Canada, Japan, Korea, and select Southeast Asian markets. Financial terms of the deal were not disclosed. Pierre Fabre Medicament will be responsible for the development and marketing of Javlor in all other countries, including Europe.

Leveraging years of research and novel chemistry, the scientists at the Pierre Fabre Research Center were able to produce a new generation product that exhibits unique pharmacologic properties that both companies believe may provide a safe and effective treatment for people with cancer.

On a worldwide annual basis, there are approximately 10 million new cases and a total of 22 million people living with cancer.

About Pierre Fabre Medicament R&D

The Pierre Fabre Group, the second largest independent laboratory in France, employs some 9,000 people, and achieved 1.43 billion euros in sales in 2003. Operating in the area of ethical medicine, health products and dermo- cosmetic with the brands Avene, Ducray, A-derma, Galenic, Klorane and Rene Furterer, it achieves 44% of its business abroad. Pierre Fabre Medicament, the pharmaceutical branch of the Pierre Fabre Group, made Research and Development its core business and the key to its future. With over 1 000 researchers, Pierre Fabre Medicament dedicates 23% of its annual sales to R&D, in five major therapeutic areas in terms of public health: oncology (the priority R&D area of Pierre Fabre Medicament, with 50% of all R&D expenses), central nervous system, cardiology, internal medicine/urology, dermatology.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol- Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward- looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, competitive product development, governmental regulations and difficulties and delays in product development. There can be no guarantee that the product described in this release will receive regulatory approval, or that it will prove to be commercially successful. For further details and a discussion of these and other risks and uncertainties, see the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Bristol-Myers Squibb Company; Pierre Fabre Medicament S.A.

CONTACT: Kathy Baum, Corporate Affairs, +1-609-252-4227, or JohnElicker, Investor Relations, +1-212-546-3775, or Susan Walser, InvestorRelations, +1-212-546-4631, all of Bristol-Myers Squibb; or AlexandrineUrbain, Pierre Fabre SA, medical & scientific communication dept,+33-1-49-10-80-00



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES